Ritter Pharmaceuticals has named Gerald T. Proehl the seventh member of its board of directors.
Ritter Pharmaceuticals develops novel therapeutics that modulate the gut microbiome for the treatment of gastrointestinal diseases.
Mr. Proehl has previous experience as the president and CEO of Santarus. During his time there, he oversaw the development and commercialization of the GI products UCERIS and Zegerid.